Fernanda P. Silveira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Fernanda P. Silveira has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Richard Kent Zimmerman
University of Pittsburgh
5 shared publications - Emily Toth Martin
Department of Epidemiology, University of Michigan School of Public health
4 shared publications - Goundappa K. Balasubramani
University of Pittsburgh
4 shared publications - Manjusha Gaglani
Baylor Scott & White Health , Temple, TX
4 shared publications - Jill Morris Ferdinands
Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia
3 shared publications - Mary Patricia Nowalk
University of Pittsburgh, Pittsburgh, PA, USA
3 shared publications
Latest Publications
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
1161. Effectiveness of the Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Infections in Outpatient Immunocompromised Adults, 2017-2018
While the number of immunocompromised (IC) individuals continues to rise, the existing literature on influenza vaccine effectiveness (VE) in IC populations is limited. IC individuals have a higher risk of severe influenza and influenza-related hospitalizations, and understanding the VE of the seasonal influenza vaccines in IC populations remains paramount. Using 2017-2018 US Flu VE Network (US Flu VE) data, we examined the VE of the 2017-2018 seasonal influenza vaccine against symptomatic influenza in outpatient settings among IC adults. Patients were enrolled from outpatient sites in five states. IC status was determined by ICD-10 codes. We used logistic regression and adjusted for enrollment site, race, self-reported general health status, age, and onset date of symptoms. Separate models were used to calculate and compare the VE for non-IC and IC among outpatient adults >18 years. We observed lower VE against symptomatic influenza among non-hospitalized patients with immunocompromising conditions though the difference was not statistically significant. This study demonstrates the capacity to study a large IC population using an existing influenza VE network and contributes to the literature to support large, multicenter VE studies for IC populations. Richard K. Zimmerman, MA; MD; MPH; MS, Sanofi Pasteur: Grant/Research Support MaryPatricia Nowalk, PhD, RDN, Merck & Co.: Grant/Research Support|Merck & Co.: Honoraria|Sanofi: Grant/Research Support Fernanda P. Silveira, MD, Ansun: Grant/Research Support|Eurofins Viracor: Advisor/Consultant|Janssen: Advisor/Consultant|Merck: Grant/Research Support|Regeneron: Grant/Research Support|Takeda: Advisor/Consultant Emily T. Martin, PhD, MPH, Merck: Grant/Research Support
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access1161. Effectiveness of the Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Infections in Outpatient Immunocompromised Adults, 2017-2018
While the number of immunocompromised (IC) individuals continues to rise, the existing literature on influenza vaccine effectiveness (VE) in IC populations is limited. IC individuals have a higher risk of severe influenza and influenza-related hospitalizations, and understanding the VE of the seasonal influenza vaccines in IC populations remains paramount. Using 2017-2018 US Flu VE Network (US Flu VE) data, we examined the VE of the 2017-2018 seasonal influenza vaccine against symptomatic influenza in outpatient settings among IC adults. Patients were enrolled from outpatient sites in five states. IC status was determined by ICD-10 codes. We used logistic regression and adjusted for enrollment site, race, self-reported general health status, age, and onset date of symptoms. Separate models were used to calculate and compare the VE for non-IC and IC among outpatient adults >18 years. We observed lower VE against symptomatic influenza among non-hospitalized patients with immunocompromising conditions though the difference was not statistically significant. This study demonstrates the capacity to study a large IC population using an existing influenza VE network and contributes to the literature to support large, multicenter VE studies for IC populations. Richard K. Zimmerman, MA; MD; MPH; MS, Sanofi Pasteur: Grant/Research Support MaryPatricia Nowalk, PhD, RDN, Merck & Co.: Grant/Research Support|Merck & Co.: Honoraria|Sanofi: Grant/Research Support Fernanda P. Silveira, MD, Ansun: Grant/Research Support|Eurofins Viracor: Advisor/Consultant|Janssen: Advisor/Consultant|Merck: Grant/Research Support|Regeneron: Grant/Research Support|Takeda: Advisor/Consultant Emily T. Martin, PhD, MPH, Merck: Grant/Research Support
- Open Access
- 1 July 2023
- Published by Universidade Estadual de Londrina in Discursos Fotográficos
- Vol. 20 (34) , 129-142
Mentir no plural: uma proposta de classificação das fake news
O fenômeno da desinformação na era das redes sociais tem na disseminação das notícias falsas um dos seus pilares. O objetivo deste artigo é identificar padrões na produção de notícias falsas divulgadas durante a pandemia de Covid-19 para justificar as políticas negacionistas adotadas pelo governo brasileiro. O corpus foi constituído por 142 matérias checadas pelas agências Lupa e Fato ou Fake entre maio e outubro de 2021. A pesquisa exploratória, de caráter quali-quantitativo, empregou análise de conteúdo e método dedutivo. Foram identificadas duas categorias de notícias falsas: invenção e adulteração; sendo esta última dividida em quatro subcategorias: distorção, descontextualização, fraude, falsa simetria. Ainda que 50% das notícias falsas tenham sido forjadas por processos primários de invenção, a análise identifica que a outra metade foi constituída por conteúdos distorcidos que indicam uma estrutura complexa de financiamento da produção.
- 1 July 2023
- Published by Universidade Estadual de Londrina in Discursos Fotográficos
- Vol. 20 (34) , 129-142
Open AccessMentir no plural: uma proposta de classificação das fake news
O fenômeno da desinformação na era das redes sociais tem na disseminação das notícias falsas um dos seus pilares. O objetivo deste artigo é identificar padrões na produção de notícias falsas divulgadas durante a pandemia de Covid-19 para justificar as políticas negacionistas adotadas pelo governo brasileiro. O corpus foi constituído por 142 matérias checadas pelas agências Lupa e Fato ou Fake entre maio e outubro de 2021. A pesquisa exploratória, de caráter quali-quantitativo, empregou análise de conteúdo e método dedutivo. Foram identificadas duas categorias de notícias falsas: invenção e adulteração; sendo esta última dividida em quatro subcategorias: distorção, descontextualização, fraude, falsa simetria. Ainda que 50% das notícias falsas tenham sido forjadas por processos primários de invenção, a análise identifica que a outra metade foi constituída por conteúdos distorcidos que indicam uma estrutura complexa de financiamento da produção.
- Open Access
- 14 June 2023
- Published by Universidade Federal da Paraíba in Culturas Midiáticas
- Vol. 18
Fake news e Covid-19
Os trabalhos da Comissão Parlamentar de Inquérito (CPI) aberta em 2021 pelo Senado brasileiro para investigar a condução do combate à pandemia pelo governo tiveram grande repercussão na imprensa e na sociedade. Esteve em curso neste período uma disputa pela agenda do debate público, para além dos pronunciamentos oficiais. Essa outra disputa tinha como ferramenta a elaboração e veiculação de notícias falsas. Neste artigo analisamos as fake news veiculadas durante a CPI da Pandemia a partir do trabalho de checagem feito pelas agências Lupa e Fato ou Fake. Concluímos que as fake news foram usadas em larga escala e de forma sistemática para tentar controlar a agenda do debate público e justificar medidas do governo. Para dar conta dessa análise usamos o conceito de verdade factual em Hannah Arendt e a classificação de fake news proposta por Eugênio Bucci.
- 14 June 2023
- Published by Universidade Federal da Paraíba in Culturas Midiáticas
- Vol. 18
Open AccessFake news e Covid-19
Os trabalhos da Comissão Parlamentar de Inquérito (CPI) aberta em 2021 pelo Senado brasileiro para investigar a condução do combate à pandemia pelo governo tiveram grande repercussão na imprensa e na sociedade. Esteve em curso neste período uma disputa pela agenda do debate público, para além dos pronunciamentos oficiais. Essa outra disputa tinha como ferramenta a elaboração e veiculação de notícias falsas. Neste artigo analisamos as fake news veiculadas durante a CPI da Pandemia a partir do trabalho de checagem feito pelas agências Lupa e Fato ou Fake. Concluímos que as fake news foram usadas em larga escala e de forma sistemática para tentar controlar a agenda do debate público e justificar medidas do governo. Para dar conta dessa análise usamos o conceito de verdade factual em Hannah Arendt e a classificação de fake news proposta por Eugênio Bucci.
- Open Access
- 29 May 2021
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 73 (12) , 2240-2247
Coronavirus disease 2019 (COVID-19) Versus Influenza in Hospitalized Adult Patients in the United States: Differences in Demographic and Severity Indicators
Background: Novel coronavirus disease 2019 (COVID-19) is frequently compared with influenza. The Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN) conducts studies on the etiology and characteristics of U.S. hospitalized adults with influenza. It began enrolling patients with COVID-19 hospitalizations in March 2020. Patients with influenza were compared with those with COVID-19 in the first months of the U.S. epidemic. Methods: Adults aged ≥ 18 years admitted to hospitals in 4 sites with acute respiratory illness were tested by real-time reverse transcription polymerase chain reaction for influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing COVID-19. Demographic and illness characteristics were collected for influenza illnesses during 3 seasons 2016–2019. Similar data were collected on COVID-19 cases admitted before June 19, 2020. Results: Age groups hospitalized with COVID-19 (n = 914) were similar to those admitted with influenza (n = 1937); 80% of patients with influenza and 75% of patients with COVID-19 were aged ≥50 years. Deaths from COVID-19 that occurred in younger patients were less often related to underlying conditions. White non-Hispanic persons were overrepresented in influenza (64%) compared with COVID-19 hospitalizations (37%). Greater severity and complications occurred with COVID-19 including more ICU admissions (AOR = 15.3 [95% CI: 11.6, 20.3]), ventilator use (AOR = 15.6 [95% CI: 10.7, 22.8]), 7 additional days of hospital stay in those discharged alive, and death during hospitalization (AOR = 19.8 [95% CI: 12.0, 32.7]). Conclusions: While COVID-19 can cause a respiratory illness like influenza, it is associated with significantly greater severity of illness, longer hospital stays, and higher in-hospital deaths.
- 29 May 2021
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 73 (12) , 2240-2247
Open AccessCoronavirus disease 2019 (COVID-19) Versus Influenza in Hospitalized Adult Patients in the United States: Differences in Demographic and Severity Indicators
Background: Novel coronavirus disease 2019 (COVID-19) is frequently compared with influenza. The Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN) conducts studies on the etiology and characteristics of U.S. hospitalized adults with influenza. It began enrolling patients with COVID-19 hospitalizations in March 2020. Patients with influenza were compared with those with COVID-19 in the first months of the U.S. epidemic. Methods: Adults aged ≥ 18 years admitted to hospitals in 4 sites with acute respiratory illness were tested by real-time reverse transcription polymerase chain reaction for influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing COVID-19. Demographic and illness characteristics were collected for influenza illnesses during 3 seasons 2016–2019. Similar data were collected on COVID-19 cases admitted before June 19, 2020. Results: Age groups hospitalized with COVID-19 (n = 914) were similar to those admitted with influenza (n = 1937); 80% of patients with influenza and 75% of patients with COVID-19 were aged ≥50 years. Deaths from COVID-19 that occurred in younger patients were less often related to underlying conditions. White non-Hispanic persons were overrepresented in influenza (64%) compared with COVID-19 hospitalizations (37%). Greater severity and complications occurred with COVID-19 including more ICU admissions (AOR = 15.3 [95% CI: 11.6, 20.3]), ventilator use (AOR = 15.6 [95% CI: 10.7, 22.8]), 7 additional days of hospital stay in those discharged alive, and death during hospitalization (AOR = 19.8 [95% CI: 12.0, 32.7]). Conclusions: While COVID-19 can cause a respiratory illness like influenza, it is associated with significantly greater severity of illness, longer hospital stays, and higher in-hospital deaths.
- Open Access
- 3 January 2021
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 73 (11) , e4353-e4360
Effectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Immunocompromised Adults
Yearly influenza immunization is recommended for immunocompromised (IC) individuals, although immune responses are lower than that for the nonimmunocompromised and the data on vaccine effectiveness (VE) in the IC is scarce. We evaluated VE against influenza-associated hospitalization among IC adults. We analyzed data from adults ≥ 18 years hospitalized with acute respiratory illness (ARI) during the 2017–2018 influenza season at 10 hospitals in the United States. IC adults were identified using prespecified case definitions using electronic medical record data. VE was evaluated with a test-negative case-control design using multivariable logistic regression with polymerase chain reaction–confirmed influenza as the outcome and vaccination status as the exposure, adjusting for age, enrolling site, illness onset date, race, days from onset to specimen collection, self-reported health, and self-reported hospitalizations. Of 3524 adults hospitalized with ARI, 1210 (34.3%) had an immunocompromising condition. IC adults were more likely to be vaccinated than non-IC (69.5% vs 65.2%) and less likely to have influenza (22% vs 27.8%). The mean age did not differ among IC and non-IC (61.4 vs 60.8 years of age). The overall VE against influenza hospitalization, including immunocompetent adults, was 33% (95% confidence interval [CI], 21–44). VE among IC vs non-IC adults was lower at 5% (95% CI, –29% to 31%) vs 41% (95% CI, 27–52) (P < .05 for interaction term). VE in 1 influenza season was very low among IC individuals. Future efforts should include evaluation of VE among the different immunocompromising conditions and whether enhanced vaccines improve the suboptimal effectiveness among the immunocompromised.
- 3 January 2021
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 73 (11) , e4353-e4360
Open AccessEffectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Immunocompromised Adults
Yearly influenza immunization is recommended for immunocompromised (IC) individuals, although immune responses are lower than that for the nonimmunocompromised and the data on vaccine effectiveness (VE) in the IC is scarce. We evaluated VE against influenza-associated hospitalization among IC adults. We analyzed data from adults ≥ 18 years hospitalized with acute respiratory illness (ARI) during the 2017–2018 influenza season at 10 hospitals in the United States. IC adults were identified using prespecified case definitions using electronic medical record data. VE was evaluated with a test-negative case-control design using multivariable logistic regression with polymerase chain reaction–confirmed influenza as the outcome and vaccination status as the exposure, adjusting for age, enrolling site, illness onset date, race, days from onset to specimen collection, self-reported health, and self-reported hospitalizations. Of 3524 adults hospitalized with ARI, 1210 (34.3%) had an immunocompromising condition. IC adults were more likely to be vaccinated than non-IC (69.5% vs 65.2%) and less likely to have influenza (22% vs 27.8%). The mean age did not differ among IC and non-IC (61.4 vs 60.8 years of age). The overall VE against influenza hospitalization, including immunocompetent adults, was 33% (95% confidence interval [CI], 21–44). VE among IC vs non-IC adults was lower at 5% (95% CI, –29% to 31%) vs 41% (95% CI, 27–52) (P < .05 for interaction term). VE in 1 influenza season was very low among IC individuals. Future efforts should include evaluation of VE among the different immunocompromising conditions and whether enhanced vaccines improve the suboptimal effectiveness among the immunocompromised.
- Open Access
Effectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Immunocompromised Adults
Background: Yearly influenza immunization is recommended for immunocompromised (IC) individuals, although immune responses are lower than that for the non-immunocompromised and the data on vaccine effectiveness (VE) in the IC is scarce. We evaluated VE against influenza-associated hospitalization among IC adults. Methods: We analyzed data from adults ≥ 18 years hospitalized with acute respiratory illness (ARI) during the 2017-2018 influenza season at 10 hospitals in the United States. IC adults were identified using pre-specified case-definitions, utilizing electronic medical record data. VE was evaluated with a test-negative case-control design using multivariate logistic regression with PCR-confirmed influenza as the outcome and vaccination status as the exposure, adjusting for age, enrolling site, illness onset date, race, days from onset to specimen collection, self-reported health, and self-reported hospitalizations. Results: Of 3,524 adults hospitalized with ARI, 1,210 (34.3%) had an immunocompromising condition. IC adults were more likely to be vaccinated than non-IC (69.5% vs 65.2%), and less likely to have influenza (22% vs 27.8%). The mean age did not differ among IC and non-IC (61.4 vs 60.8 years old). The overall VE against influenza hospitalization, including immunocompetent adults, was 33% (95% CI, 21% to 44%). VE among IC vs non-IC adults was lower at 5% (−29% to 31%) vs. 41% (27% to 52%) (p<0.05 for interaction term). Conclusions: VE in one influenza season was very low among IC individuals. Future efforts should include evaluation of VE among the different immunocompromising conditions and whether enhanced vaccines improve the suboptimal effectiveness among the immunocompromised.
Open AccessEffectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Immunocompromised Adults
Background: Yearly influenza immunization is recommended for immunocompromised (IC) individuals, although immune responses are lower than that for the non-immunocompromised and the data on vaccine effectiveness (VE) in the IC is scarce. We evaluated VE against influenza-associated hospitalization among IC adults. Methods: We analyzed data from adults ≥ 18 years hospitalized with acute respiratory illness (ARI) during the 2017-2018 influenza season at 10 hospitals in the United States. IC adults were identified using pre-specified case-definitions, utilizing electronic medical record data. VE was evaluated with a test-negative case-control design using multivariate logistic regression with PCR-confirmed influenza as the outcome and vaccination status as the exposure, adjusting for age, enrolling site, illness onset date, race, days from onset to specimen collection, self-reported health, and self-reported hospitalizations. Results: Of 3,524 adults hospitalized with ARI, 1,210 (34.3%) had an immunocompromising condition. IC adults were more likely to be vaccinated than non-IC (69.5% vs 65.2%), and less likely to have influenza (22% vs 27.8%). The mean age did not differ among IC and non-IC (61.4 vs 60.8 years old). The overall VE against influenza hospitalization, including immunocompetent adults, was 33% (95% CI, 21% to 44%). VE among IC vs non-IC adults was lower at 5% (−29% to 31%) vs. 41% (27% to 52%) (p<0.05 for interaction term). Conclusions: VE in one influenza season was very low among IC individuals. Future efforts should include evaluation of VE among the different immunocompromising conditions and whether enhanced vaccines improve the suboptimal effectiveness among the immunocompromised.
- Open Access
- 29 July 2020
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 223 (6) , 1073-1077
Risk Factors for Cytomegalovirus Viremia following Liver Transplantation With a Seropositive Donor and Seronegative Recipient Receiving Antiviral Therapy
The risk factors for development of viremia in high-risk donor cytomegalovirus (CMV)-seropositive and recipient CMV-seronegative (D+R−) transplant recipients are incompletely defined. The study population comprised patients in the preemptive therapy (PET) arm of a randomized, controlled trial of PET versus prophylaxis using valganciclovir in D+R− liver transplant recipients. Weekly surveillance monitoring for viremia for 100 days was performed using a sensitive CMV-DNA polymerase chain reaction assays. Risk factors for viremia and time to onset (≤4 vs >4 weeks) of viremia were examined using logistic regression models. Viremia developed in 84% (79/94) of recipients and older donor age was the only independent factor associated with viremia (odds ratio, 2.20 for each quartile increase in donor age; 95% confidence interval [CI], 1.07–4.52; P = .031). Recipients who developed early-onset viremia (within 4 weeks) also had significantly older donors than those with later-onset viremia (difference in age 10.1 years; 95% CI, 2–19; P = .03). Older donor age was an independent predictor of viremia and earlier-onset of viremia in D+R− liver transplant recipients. Future studies should assess the mechanistic links underlying this novel association. NCT01552369.
- 29 July 2020
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 223 (6) , 1073-1077
Open AccessRisk Factors for Cytomegalovirus Viremia following Liver Transplantation With a Seropositive Donor and Seronegative Recipient Receiving Antiviral Therapy
The risk factors for development of viremia in high-risk donor cytomegalovirus (CMV)-seropositive and recipient CMV-seronegative (D+R−) transplant recipients are incompletely defined. The study population comprised patients in the preemptive therapy (PET) arm of a randomized, controlled trial of PET versus prophylaxis using valganciclovir in D+R− liver transplant recipients. Weekly surveillance monitoring for viremia for 100 days was performed using a sensitive CMV-DNA polymerase chain reaction assays. Risk factors for viremia and time to onset (≤4 vs >4 weeks) of viremia were examined using logistic regression models. Viremia developed in 84% (79/94) of recipients and older donor age was the only independent factor associated with viremia (odds ratio, 2.20 for each quartile increase in donor age; 95% confidence interval [CI], 1.07–4.52; P = .031). Recipients who developed early-onset viremia (within 4 weeks) also had significantly older donors than those with later-onset viremia (difference in age 10.1 years; 95% CI, 2–19; P = .03). Older donor age was an independent predictor of viremia and earlier-onset of viremia in D+R− liver transplant recipients. Future studies should assess the mechanistic links underlying this novel association. NCT01552369.
- Open Access
- 1 June 2019
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 6 (6) , ofz231
Determination of Eligibility for Influenza Research: A Clinical Informatics Approach
Background: A clinical informatics algorithm (CIA) was developed to systematically identify potential enrollees for a test-negative, case-control study to determine influenza vaccine effectiveness, to improve enrollment over manual records review. Further testing may enhance the CIA for increased efficiency. Methods: The CIA generated a daily screening list by querying all medical record databases for patients admitted in the last 3 days, using specified terms and diagnosis codes located in admission notes, emergency department notes, chief complaint upon registration, or presence of a respiratory viral panel charge or laboratory result (RVP). Classification and regression tree analysis (CART) and multivariable logistic regression were used to refine the algorithm. Results: Using manual records review, 204 patients (<4/day) were approached and 144 were eligible in the 2014–2015 season compared with 3531 (12/day) patients who were approached and 1136 who were eligible in the 2016–2017 season using a CIA. CART analysis identified RVP as the most important indicator from the CIA list for determining eligibility, identifying 65%–69% of the samples and predicting 1587 eligible patients. RVP was confirmed as the most significant predictor in regression analysis, with an odds ratio (OR) of 4.9 (95% confidence interval [CI], 4.0–6.0). Other significant factors were indicators in admission notes (OR, 2.3 [95% CI, 1.9–2.8]) and emergency department notes (OR, 1.8 [95% CI, 1.4–2.3]). Conclusions: This study supports the benefits of a CIA to facilitate recruitment of eligible participants in clinical research over manual records review. Logistic regression and CART identified potential eligibility screening criteria reductions to improve the CIA’s efficiency.
- 1 June 2019
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 6 (6) , ofz231
Open AccessDetermination of Eligibility for Influenza Research: A Clinical Informatics Approach
Background: A clinical informatics algorithm (CIA) was developed to systematically identify potential enrollees for a test-negative, case-control study to determine influenza vaccine effectiveness, to improve enrollment over manual records review. Further testing may enhance the CIA for increased efficiency. Methods: The CIA generated a daily screening list by querying all medical record databases for patients admitted in the last 3 days, using specified terms and diagnosis codes located in admission notes, emergency department notes, chief complaint upon registration, or presence of a respiratory viral panel charge or laboratory result (RVP). Classification and regression tree analysis (CART) and multivariable logistic regression were used to refine the algorithm. Results: Using manual records review, 204 patients (<4/day) were approached and 144 were eligible in the 2014–2015 season compared with 3531 (12/day) patients who were approached and 1136 who were eligible in the 2016–2017 season using a CIA. CART analysis identified RVP as the most important indicator from the CIA list for determining eligibility, identifying 65%–69% of the samples and predicting 1587 eligible patients. RVP was confirmed as the most significant predictor in regression analysis, with an odds ratio (OR) of 4.9 (95% confidence interval [CI], 4.0–6.0). Other significant factors were indicators in admission notes (OR, 2.3 [95% CI, 1.9–2.8]) and emergency department notes (OR, 1.8 [95% CI, 1.4–2.3]). Conclusions: This study supports the benefits of a CIA to facilitate recruitment of eligible participants in clinical research over manual records review. Logistic regression and CART identified potential eligibility screening criteria reductions to improve the CIA’s efficiency.
- Open Access
- 1 August 2018
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 4 (8) , e372
A Prospective Observational Study of Hypogammaglobulinemia in the First Year After Lung Transplantation
Background: Immunosuppressive therapies have led to improved survival for lung transplant (LT) recipients but these therapies can lead to hypogammaglobulinemia (HGG) and potentially an increased risk of infection. Large prospective studies have not been performed to evaluate the impact of HGG on outcomes for LT recipients. Methods: This is a single-center prospective observational study of LT recipients. Pretransplant and posttransplant IgG levels were measured and related to infection, rejection, antibiotic use, and immunosuppression use. Results: One hundred thirty-three LT recipients were prospectively evaluated. Pretransplant IgG values were higher than IgG values at the time of transplant or any time thereafter (all P < 0.0001). Severe HGG (IgG < 400 mg/dL) was highest at the time of transplant (32.4%) while at 3, 6, 9, and 12 months posttransplant the prevalence of severe HGG was 7.4%, 7.5%, 8.9%, and 6.3%, respectively. Severe HGG was associated with 2 or more pneumonias (P = 0.0006) and increased number of antibiotic courses (P = 0.003) compared with the subjects without severe HGG. Pretransplant IgG level and less than 30% of pretransplant protective pneumococcal antibody levels were identified as pretransplant risk factors for severe HGG. In multivariate analysis, chronic obstructive pulmonary disease as the underlying disease and the use of basiliximab as the induction agent in conjunction with higher prednisone and mycophenolate dosing were most predictive of severe HGG (P = 0.005), whereas the combination of age, severe HGG and number of acute steroid courses were most predictive of total days of pneumonia (P = 0.0001). Conclusions: Our large prospective study identifies risk factors for severe HGG after LT and demonstrates that LT recipients with severe HGG are at increased risk for recurrent pneumonias and more antibiotic courses.
- 1 August 2018
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 4 (8) , e372
Open AccessA Prospective Observational Study of Hypogammaglobulinemia in the First Year After Lung Transplantation
Background: Immunosuppressive therapies have led to improved survival for lung transplant (LT) recipients but these therapies can lead to hypogammaglobulinemia (HGG) and potentially an increased risk of infection. Large prospective studies have not been performed to evaluate the impact of HGG on outcomes for LT recipients. Methods: This is a single-center prospective observational study of LT recipients. Pretransplant and posttransplant IgG levels were measured and related to infection, rejection, antibiotic use, and immunosuppression use. Results: One hundred thirty-three LT recipients were prospectively evaluated. Pretransplant IgG values were higher than IgG values at the time of transplant or any time thereafter (all P < 0.0001). Severe HGG (IgG < 400 mg/dL) was highest at the time of transplant (32.4%) while at 3, 6, 9, and 12 months posttransplant the prevalence of severe HGG was 7.4%, 7.5%, 8.9%, and 6.3%, respectively. Severe HGG was associated with 2 or more pneumonias (P = 0.0006) and increased number of antibiotic courses (P = 0.003) compared with the subjects without severe HGG. Pretransplant IgG level and less than 30% of pretransplant protective pneumococcal antibody levels were identified as pretransplant risk factors for severe HGG. In multivariate analysis, chronic obstructive pulmonary disease as the underlying disease and the use of basiliximab as the induction agent in conjunction with higher prednisone and mycophenolate dosing were most predictive of severe HGG (P = 0.005), whereas the combination of age, severe HGG and number of acute steroid courses were most predictive of total days of pneumonia (P = 0.0001). Conclusions: Our large prospective study identifies risk factors for severe HGG after LT and demonstrates that LT recipients with severe HGG are at increased risk for recurrent pneumonias and more antibiotic courses.
- 1 May 2016
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 35 (5) , 560-563
The Zika epidemics and transplantation
- 1 May 2016
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 35 (5) , 560-563
The Zika epidemics and transplantation